Is there any data to support to use of Brentuximab in the up-front setting in the treatment of Hodgkin lymphomas?

Currently, Brentuximab vedotin is only approved in Hodgkin lymphoma 1) following failure of 2 multi-agent regimens or ASCT and 2) for post-ASCT maintenance. However, there are several ongoing phase II and III trials in both the US and EU examining Brentuximab vedotin in the up-front setting. The largest of these trials is the ECHELON-1 study, which is a large phase III study examining ABVD vs AVD-BV as upfront treatment for advanced stage HL.

At our institution, we have a pilot multi-institution...